Glenmark Pharmaceuticals widened its loss for the quarter ended March 31, 2024 to Rs 1238.65 crore in comparison to a loss of Rs 549.49 crore recorded during the same period last year. It posted revenue from operations at Rs 3062.95 crore, up 2.1 per cent as against Rs 3000.51 crore during the fourth quarter of FY23. The company EBITDA stood at Rs 504.2 crore, up 26.7 per cent on-year.
The company board also recommended a dividend @ 250 per cent i.e. Rs 2.5 per share (face value of Re 1 each) on the equity share capital of the company for the financial year 2023-24 subject to the approval of the shareholders at the ensuing Annual General Meeting.
Q4 Results 2024 Updates: NTPC, Hindalco Industries, Ashok Leyland, Glenmark Pharma, Coffee Day Enterprises, more to announce earnings today
Flipkart raises $350 million from Google in latest funding round
EaseMyTrip.com posts Q4 loss of Rs 15.75 crore, revenue up 40.7% on-year; know more about co. performance across key biz
TCS COO N Ganapathy Subramaniam to retire effective May 20; CEO says won’t appoint a new COO
From: financialexpress
Financial News
